Six-month net revenues of $23.4 million, a 67% increase compared to first half 2022
Delivered its eighth consecutive quarter of positive Adjusted EBITDA of $3.2M, a 1500% increase compared to Q2 2022
Continued to increase growing capacity to meet customer demand by activating an additional growing zone in its expanding Valleyfield Facility
All financial results are reported in Canadian dollars, unless otherwise stated.
MONTREAL, April 24, 2023 /PRNewswire/ - Cannara Biotech Inc. ("Cannara" or the "Company") (TSXV: LOVE) (OTCQB: LOVFF) (FRA: 8CB), a vertically integrated producer of premium-grade cannabis and derivative product offerings at affordable prices with two mega facilities based in Qubec spanning over 1,650,000 sq. ft., today announced its fiscal second quarter 2023 financial and operating results for the three and six-month periods ended February 28, 2023.
Cannara Biotech Inc. reports Q2 2023 Financial Results with quarterly net revenues of $13 million, a 76% increase compared to Q2 2022 (prnewswire.com)